Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy

Haemophilia

Volumn 19, Issue 6, 2013, Pages 808-813

  Bjorkman S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dose tailoring; Factor IX; Pharmacokinetics

Indexed keywords

PLASMA DERIVED BLOOD CLOTTING FACTOR IX; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

BLOOD SAMPLING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HEMOPHILIA B; HUMAN; MEAN RESIDENCE TIME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STEADY STATE; STOCHASTIC MODEL;

DOSE TAILORING; FACTOR IX; PHARMACOKINETICS;

COAGULANTS; FACTOR IX; HALF-LIFE; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS;

EID: 84886640646     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12216     Document Type: Review

References (37)

1. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
2. Gioia KP, Bouhasin D. Call for post-licensing human pharmacokinetic studies of administration of recombinant factor IX. Haemophilia 1998; 4: 67.
3. Courter SG, Beach KJ. Call for post-licensing human pharmacokinetic studies of administration of recombinant factor IX. Haemophilia 1998; 4: 136-7.
4. Kisker CT, Eisberg A, Schwartz B and the Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279-84.
5. Morfini M, Laguna P, Leissinger C. Factor IX pharmacokinetics: differences between plasma-derived and recombinant products and the clinical and economic implications: a meeting report. Haemophilia 2008; 14: 873-5.
6. Santagostino E. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications. Haemophilia 2010; 16(Suppl. 6): 13-7.
7. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-84.
8. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
9. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfus 2011; 9: 60-9.
10. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
11. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant blood coagulation factor IX in previously untreated patients with severe and moderately severe hemophilia B. Blood 2005; 105: 518-25.
12. Monahan PE, Liesner R, Sullivan ST, Ramirez ME, Kelly P, Roth DA. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-8.
13. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
14. Schimpf K, Baumann P. Die ambulante Dauerbehandlung der Hämophilie B. Dtsch Med Wochenshr 1976; 101: 233-8.
15. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
16. Lissitchkov T, Matysiak M, Zawilska K et al. An open clinical study assessing the efficacy and safety of factor IX Grifols, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2010; 16: 240-6.
17. Lissitchkov T, Matysiak M, Zavilska K et al. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
18. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl. 1): 101-10.
19. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
20. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18(Suppl. 4): 131-5.
21. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
22. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
23. Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305-12.
24. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
25. Lee M, Morfini M, Schulman S, Ingerslev J and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The design and analysis of pharmacokinetic studies of coagulation factors. 2001. Available at http://www.isth.org/Publications/OfficialCommunications/Factor8and9/Pharmacokinetic.aspx. Accessed May 10, 2013.
26. Udata C, Sullivan S, Kelly P, Roth DA, Meng X. Population pharmacokinetic modeling of BeneFIX in pediatric and adult patients with hemophilia B demonstrates weight as an important factor contributing to inter-patient PK variability. Blood 2008; 112: Abstract 1218.
27. Björkman S, Åhlén V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol 2012; 68: 969-77.
28. Björkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013; 19: doi:10.1111/hae.12188.
29. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
30. Björkman S. Collins P; for the Project on Factor VIII/Factor IX Pharmacokinetics of the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180-2.
31. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B: methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
32. White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, the Mononine Study Group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost 1995; 73: 779-84.
33. Poon M-C, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
34. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2-8.
35. Martorell M, Altisent C, Parra R. Recovery of recombinant factor IX determined in clinical practice. Haemophilia 2009; 15: 840-2.
36. Centers for Disease Control and Prevention. Atlanta, GA: Clinical Growth Charts. Available at http://www.cdc.gov/growthcharts/ Accessed July 30, 2012.
37. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.